On 12 Nov 2026 Globe Life closed at $160.11, +15.4% this year; market cap $12.52bn, P/E 10.6.
Financials · Life & Health Insurance · NYSE · United States
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance, and Investments. The company offers whole, term, and other life insurance products, as well as life insurance for children; Medicare supplement and limited-benefit supplemental health insurance products, such as accident, cancer, critical illness, heart, intensive care, and other health products; and final expense, accidental death, mortgage protection, and hospital insurance products. It sells its products through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers. The company was formerly known as Torchmark Corporation and changed its name to Globe Life Inc. in August 2019. Globe Life Inc. was founded in 1900 and is headquartered in McKinney, Texas.
| Market cap | $12.52bn |
| P/E (trailing) | 10.6 |
| EPS (TTM) | $15.15 |
| Beta | 0.46 |
| Dividend | $1.32 |
| Dividend yield | 0.82% |
| Ex-dividend date | 8 Jan 2027 |
| Latest report | 21 Oct 2026 |
| Next earnings | 20 Jan 2027 |
| YTD | +15.4% |
| 1Y | +20.5% |
| 3Y | +12.0% |
| 5Y | +12.1% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $6.00bn | $1.16bn | $1.25bn |
| 2024 | $5.78bn | $1.07bn | $1.33bn |
| 2023 | $5.45bn | $970.75m | $1.43bn |
| 2022 | $5.21bn | $739.70m | $1.39bn |
| 2021 | $5.11bn | $744.96m | $1.40bn |
We publish no single base value for Globe Life. Our valuation methods put it between $143.57 and $391.56 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.